Experts at the forefront of research into myeloproliferative neoplasms (MPN) launched today a new global educational website dedicated to improving knowledge and understanding of those malignancies.
The MPN Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on MPN. The new hub aims to enhance knowledge in MPN through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
The MPN Hub shares new data, the latest treatment options, evidence-based articles, therapy approvals, expert opinions, and international congress coverage of the most relevant meetings to hematologists, oncologists, stem cell transplanters, and other healthcare professionals, as well as researchers around the world.
MPN are clonal myeloid malignancies arising from transformed hematopoietic stem cells. They are generally characterized by unique driver mutations that influence the course of the disease. Only a few drugs have been approved so far for the treatment of thrombocythemia, polycythemia vera, and primary myelofibrosis, and new treatments are required to address current challenges in MPN, such as failure to respond to therapy, disease progression and transformation to leukemia.
The MPN Hub, was founded by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN) in 2020, and is guided by an International Steering Committee of world-leading experts in MPN, who meet regularly to discuss the content and how to support the MPN community. These international experts also share their knowledge on MPN through feature articles and expert opinions, in the form of comments on important updates and video interviews during key congresses.
"In the MPN Hub, we have gathered the most recent and most relevant information about MPN pathophysiology, clinical advances, and therapy. You will certainly find answers to your burning questions about MPN here!" Jean-Jacques Kiladjian, Chair of the MPN Hub and Professor at the Université de Paris, Paris, France.
Professor Jean-Jacques Kiladjian has joined the Steering Committee together with some of the worldwide experts in MPN and hematology-oncology research, including Professor Giovanni Barosi, Professor Tiziano Barbui, Doctor Francisco Cervantes, Professor Stefan N. Constantinescu, Assistant Professor Angela Fleischman, Professor Stéphane Giraudier, Professor Claire Harrison, Professor Chloé James, Professor Norio Komatsu, Professor Steffen Koschmieder, Associate Professor John Mascarenhas, Professor Ruben A. Mesa, Associate Professor Laura Michaelis, and Professor Alessandro M. Vannucchi.
Working in collaboration with the Steering Committee, the MPN Hub is delivered by SES who strive to bring increased knowledge and awareness to healthcare professionals via collaborative networks across the globe. SES already delivers the highly successful AML Hub, Lymphoma Hub, Multiple Myeloma Hub, and GvHD Hub, significantly raising the profile and knowledge of these rare diseases amongst the Hematology community.
The MPN Hub owes thanks to the support of its founding industry partners, Celgene (Gold), Novartis (Silver), Roche (Contributor), Kartos Therapeutics (Contributor), and AOP Orphan (Contributor), without whom the platform would not be possible.
For more information on the MPN Hub, please visit www.mpn-hub.com.
For media enquiries or to explore collaboration opportunities, please contact firstname.lastname@example.org
Press release distributed by Pressat on behalf of Scientific Education Support, on Tuesday 9 June, 2020. For more information subscribe and follow https://pressat.co.uk/